Pharmacodynamic effects of vaporized and oral cannabidiol (CBD) and vaporized CBD-dominant cannabis in infrequent cannabis users
Tory R. Spindle(Johns Hopkins University), Ryan G. Vandrey(Behavioral Pharma (United States)), Elia Goffi(Behavioral Pharma (United States)), George E. Bigelow(Johns Hopkins University), Elise M. Weerts(Johns Hopkins University), Ruth E. Winecker(RTI International), John M. Mitchell(RTI International), Edward J. Cone(National Institute on Drug Abuse), Ronald Flegel(Substance Abuse and Mental Health Services Administration)
Cited by 121
Related Papers
Association Between Initial Use of e-Cigarettes and Subsequent Cigarette Smoking Among Adolescents and Young Adults
|JAMA Pediatrics|2017|1.2k
Blood Cannabinoids. I. Absorption of THC and Formation of 11-OH-THC and THCCOOH During and After Smoking Marijuana*
|Journal of Analytical Toxicology|1992|520
Methamphetamine and Amphetamine Pharmacokinetics in Oral Fluid and Plasma after Controlled Oral Methamphetamine Administration to Human Volunteers
|Clinical Chemistry|2003|264
Acute Effects of Smoked and Vaporized Cannabis in Healthy Adults Who Infrequently Use Cannabis
|JAMA Network Open|2018|259
Changing landscape of cannabis: novel products, formulations, and methods of administration
|Current Opinion in Psychology|2019|254